Inbakicept Biosimilar – Anti-IL15 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2015; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Inbakicept Biosimilar is a novel, research-grade fusion protein that has shown promising potential as a therapeutic agent for various inflammatory and autoimmune diseases. This fusion protein is a biosimilar of Inbakicept, a recombinant protein that is currently in clinical development for the treatment of lupus nephritis and rheumatoid arthritis. Inbakicept Biosimilar is designed to specifically target and neutralize interleukin-15 (IL15), a cytokine that plays a crucial role in the pathogenesis of many autoimmune disorders.
Inbakicept Biosimilar is a fusion protein composed of two components: the extracellular domain of the human IL15 receptor alpha chain (IL15Rα) and the Fc region of human IgG1. The IL15Rα domain is responsible for binding to IL15, while the Fc region provides stability and prolongs the half-life of the fusion protein in circulation. This structure allows Inbakicept Biosimilar to act as a competitive antagonist of IL15, preventing its interaction with the IL15 receptor complex and subsequent signaling pathways.
The primary activity of Inbakicept Biosimilar is to inhibit the pro-inflammatory effects of IL15. IL15 is a cytokine that is produced by various immune cells, including T cells, B cells, and macrophages. It plays a critical role in the activation and proliferation of immune cells, as well as the production of pro-inflammatory cytokines. In autoimmune diseases, IL15 is overexpressed and contributes to the chronic inflammation and tissue damage seen in these conditions. By binding to IL15 and preventing its interaction with the IL15 receptor complex, Inbakicept Biosimilar effectively blocks the downstream inflammatory signaling pathways, reducing inflammation and tissue damage.
Moreover, Inbakicept Biosimilar has been shown to have immunomodulatory effects, including the induction of regulatory T cells and suppression of pro-inflammatory cytokine production. These additional activities further contribute to the anti-inflammatory effects of Inbakicept Biosimilar, making it a promising therapeutic agent for various autoimmune diseases.
Inbakicept Biosimilar has shown potential for the treatment of several autoimmune and inflammatory diseases, including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and inflammatory bowel disease. In preclinical studies, Inbakicept Biosimilar has demonstrated efficacy in reducing disease severity and improving clinical symptoms in animal models of these diseases.
Currently, Inbakicept Biosimilar is in the early stages of clinical development for the treatment of lupus nephritis and rheumatoid arthritis. In a phase II clinical trial for lupus nephritis, Inbakicept showed promising results in reducing disease activity and improving kidney function. In a phase I study for rheumatoid arthritis, Inbakicept was well-tolerated and showed a favorable safety profile.
Additionally, Inbakicept Biosimilar has the potential to be used in combination with other therapies, such as disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents, to enhance their efficacy and reduce the risk of adverse effects.
Inbakicept Biosimilar is a promising anti-IL15 fusion protein that has shown potential as a therapeutic agent for various autoimmune and inflammatory diseases. Its unique structure and mechanism of action make it a promising alternative to current treatments for these conditions. With ongoing clinical development and further research, Inbakicept Biosimilar has the potential to improve the lives of patients suffering from these debilitating diseases.
Keywords: Inbakicept Biosimilar, anti-IL15 fusion protein, therapeutic target, autoimmune diseases, inflammatory diseases, cytokine, IL15 receptor, biosimilar, immunomod
ProteoGenix catalogue number PX-TA2015. For research use only.
Target: Inbakicept Biosimilar – Anti-IL15 fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Inbakicept Biosimilar – Anti-IL15 fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
